A new era of cancer screening

Wednesday, June 12th, 2024 | 11:00 AM - 12:00 PM CT

As cancer rates rise, it's imperative that more cases are caught earlier, when they may be more treatable. But today's single-organ cancer screening paradigm won't be enough to stop cancer from becoming the anticipated No. 1 cause of death by 2030.

Increasingly, experts are optimistic that multi-cancer early detection (MCED) testing will enable progress in the field by catching more cases in their earliest stages. Innovative developments are underway that may soon usher in a new era for cancer screening. 

Join Tomasz Beer, MD, a globally recognized expert in early cancer detection, for a conversation on how multi-cancer early detection testing is addressing unmet screening needs, and its potential to reduce the overall burden of cancer. 

Learning points:
 
  • What we’ve learned about the potential clinical value of MCED testing from prospective clinical trials
  • Details on a robust multi-biomarker class approach to MCED test design to help maximize its potential clinical benefit
  • Key considerations for the future of MCED testing

Presenter:

Tomasz Beer - Sarah Simon

Tomasz M. Beer, MD, FACP

Chief Medical Officer and VP | Multi-cancer Early Detection | Exact Sciences